The global hepatitis b vaccine market was valued at USD 7.85 billion in 2025. The market is projected to grow from USD 8.3 billion in 2026 to USD 12.95 billion by 2034, exhibiting a compound annual growth rate of 5.72% during the forecast period. Contrive Datum Insights presents this information in its report titled "Hepatitis B Vaccine Market Size, Share & Industry Analysis, By Type (Single Antigen, Combination, Others), Distribution channel (Hospitals, Government Suppliers, Others), Age group (Pediatric, Adult, Adolescent), Technology (Recombinant, Plasma-derived), Application (Routine Immunization, Travel and Occupational Vaccination, Catch-up and Outbreak Response), and Regional Forecast, 2026-2034".
Hepatitis B vaccines are prophylactic biological products administered to prevent infection with the hepatitis B virus, delivered either as a single-antigen dose or combined with other pediatric antigens such as diphtheria, tetanus, pertussis and polio in a single injection. They are purchased primarily by national immunization programs, hospitals and clinics for routine infant and childhood schedules, and by travel clinics, occupational health providers and adult primary care practices for catch-up and at-risk vaccination. Buyers range from government health ministries negotiating large-volume tenders to private clinics purchasing smaller quantities for individual patients.
Expansion of national immunization programs in emerging markets
Expansion of national immunization programs in emerging markets is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 5.72% a year, the type lines exposed to it move fastest: Combination compounds at 7.64%, taking its share of revenue from 40% to 47% and its value from USD 3.14 billion to USD 6.09 billion.
A more favourable outcome is possible. If the bull case assumes faster-than-expected expansion of government-funded immunization programs in Asia Pacific and the Middle East and Africa alongside quicker adoption of universal adult vaccination guidance in North America and Europe, 2034 revenue reaches USD 14.25 billion instead of the USD 12.95 billion the base case carries.
On the downside, the bear case assumes slower program funding growth in price-sensitive markets and continued vaccine hesitancy that keeps adult vaccination uptake in developed markets below current guidance targets, which would hold 2034 revenue to USD 11.91 billion. Single Antigen, which carries 52% of 2025 revenue, already grows at only 4.28% against the market's 5.72%, so the largest part of the base is also its slowest.
Where the Competition Actually Sits
Two positions matter, and they are set by type. Single Antigen carries 52% of 2025 revenue (USD 4.08 billion) and is still the largest line in 2034 at 46%, hard to take from an incumbent. Combination, at 7.64%, is where the USD 7.85 billion base is redistributed. The two demand different capabilities.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Single Antigen | 52% · USD 4.08 billion | — |
| Distribution channel | Hospitals | 48% · USD 3.77 billion | Government Suppliers 6.91% |
| Age group | Pediatric | 58% · USD 4.55 billion | Adult 7.85% |
| Technology | Recombinant | 94% · USD 7.38 billion | — |
| Application | Routine Immunization | 70% · USD 5.5 billion | Travel and Occupational Vaccination 8.39% |
- Based on regional analysis, Asia Pacific led the global hepatitis b vaccine market in 2025 with 39% of global revenue at USD 3.06 billion, reaching USD 5.44 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 39% in 2025 to 42% in 2034, with revenue growing from USD 3.06 billion to USD 5.44 billion.
- At 8% of 2025 revenue and 9% by 2034, Middle East and Africa is the smallest region throughout.
- The fastest type line is Combination, forecast to compound at 7.64% through the period.
- The United States is the largest single country market at USD 1.6 billion in 2025, 20.4% of global revenue.
The study covers five axes, by type, and by distribution channel, age group, technology and application, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 11.91 billion and USD 14.25 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.